S&P rates Ameritox loan B

Standard & Poor's said that it assigned a preliminary B corporate credit rating to Ameritox Ltd.

The rating outlook is stable.

S&P assigned the company's proposed $425 million term loan due 2018 and $25 million revolving credit agreement due 2016 a preliminary rating of B and a preliminary 4 recovery rating, indicating the expectation for average (30%-50%) recovery in the event of a payment default.

The ratings on Ameritox reflects the company's extremely narrow business focus in an immature niche of the clinical laboratory services industry and its highly leveraged, owner-friendly financial risk profile, the agency said.

Ameritox's rapid growth, evidenced by nearly a doubling of revenues over the past two years, is accompanied by meaningful challenges and vulnerabilities, the agency added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.